Optimizing the Sequencing of Tyrosine Kinase Inhibitors (TKIs) in Epidermal Growth Factor Receptor (EGFR) Mutation-Positive Non-Small Cell Lung Cancer (NSCLC)
Last Updated: Wednesday, June 16, 2021
This review considers the evolving role of sequencing treatments to maximize benefits for patients with EGFR mutation-positive advanced NSCLC.
Advertisement
News & Literature Highlights